Integrating pharmacogenetics into gemcitabine dosing—time for a change?

Now's the time to find biomarkers on purpose

(2010) J. T. Auman et al.   ANNALS OF ONCOLOGY

Metronomic gemcitabine suppresses tumour growth, improves perfusion and reduces hypoxia in human pancreatic ductal adenocarcinoma

(2010) K K Y Cham et al.   BRITISH JOURNAL OF CANCER

Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma

(2010) Raphaël Maréchal et al.   CANCER

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

(2010) Chen Guang Yang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

(2010) Elisa Giovannetti et al.   CANCER RESEARCH

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

(2010) J. E. Dancey et al.   CLINICAL CANCER RESEARCH

Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?

(2010) Joseph Ciccolini et al.   Clinical Colorectal Cancer

Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients

(2010) Emiko Sugiyama et al.   CLINICAL PHARMACOKINETICS

Influence of Cytidine Deaminase on Antitumor Activity of 2'-Deoxycytidine Analogs In Vitro and In Vivo

(2010) T. Yoshida et al.   DRUG METABOLISM AND DISPOSITION

Ethnic Differences of two Non-synonymous Single Nucleotide Polymorphisms in CDA Gene

(2010) Emiko Sugiyama et al.   Drug Metabolism and Pharmacokinetics

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

(2010) Jan Gerard Maring et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

(2010) Cédric Mercier et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing

(2010) Elisa Giovannetti et al.   JOURNAL OF CLINICAL ONCOLOGY

Reply to E. Giovannetti et al

(2010) Joseph Ciccolini et al.   JOURNAL OF CLINICAL ONCOLOGY

Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics

(2010) Linda Coate et al.   JOURNAL OF CLINICAL ONCOLOGY

Population-based differences in treatment outcome following anticancer drug therapies

(2010) Brigette BY Ma et al.   LANCET ONCOLOGY

Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment

(2010) Junichi Matsubara et al.   MOLECULAR & CELLULAR PROTEOMICS

Metronomic chemotherapy: new rationale for new directions

(2010) Eddy Pasquier et al.   Nature Reviews Clinical Oncology

Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?

(2010) Emilie Moreau et al.   PEDIATRIC BLOOD & CANCER

Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer

(2010) Jin-Hyeok Hwang et al.   PLoS One

High-Resolution Melting Analysis of Sequence Variations in the Cytidine Deaminase Gene (CDA) in Patients With Cancer Treated With Gemcitabine

(2010) Caroline Raynal et al.   THERAPEUTIC DRUG MONITORING

Gemcitabine and Other New Cytotoxic Drugs: Will Any Find Their Way Into Primary Therapy?

(2010) David W. Dougherty et al.   Current Hematologic Malignancy Reports

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

(2009) H Ueno et al.   BRITISH JOURNAL OF CANCER

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer

(2009) Gabriella Ferrandina et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity

(2009) T. Okazaki et al.   CLINICAL CANCER RESEARCH

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

(2009) R. Marechal et al.   CLINICAL CANCER RESEARCH

Clinical pharmacology and pharmacogenetics of gemcitabine

(2009) Andrea Wong et al.   DRUG METABOLISM REVIEWS

Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine

(2009) Junichi Matsubara et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report

(2009) Peter D. Cole et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics

(2009) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies

(2009) Joseph Ciccolini et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel

(2009) Jaume Mora et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Serum REG4 Level Is a Predictive Biomarker for the Response to Preoperative Chemoradiotherapy in Patients With Pancreatic Cancer

(2009) Hidetoshi Eguchi et al.   PANCREAS

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers

(2009) Liang Li et al.   PLoS One

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

(2008) Fariba Navid et al.   CANCER

Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy

(2008) T. Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

(2008) B. Laquente et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders

(2008) Jose de Leon   NEUROPSYCHOPHARMACOLOGY